🇸🇬 Hu3F8 in Singapore

Hu3F8 (NAXITAMAB) regulatory status in Singapore.

Marketing authorisation

HSA

  • Status: likely_approved

Hu3F8 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in Singapore

Frequently asked questions

Is Hu3F8 approved in Singapore?

Yes. HSA has authorised it.

Who is the marketing authorisation holder for Hu3F8 in Singapore?

Y-Mabs Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.